This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: The University of Texas System. Active years: 1993.
Company Filing History:
Years Active: 1993
Title: Innovations in Immunotherapy: The Contributions of Keith Heaton
Introduction
Keith Heaton is an accomplished inventor based in Houston, Texas. He is known for his significant contributions to the field of immunotherapy, particularly through his innovative research on interleukin-2 analogues. His work aims to enhance the efficacy of immunotherapy while minimizing toxicity, making strides in cancer treatment and other immune-related therapies.
Latest Patents
Keith Heaton holds a patent for "Low toxicity interleukin-2 analogues for use in immunotherapy." This patent focuses on the properties of two recombinant human IL-2 analogues with specific mutations. The analogues were analyzed and compared to native IL-2, revealing their ability to bind to the intermediate IL-2 receptor while minimizing interaction with the high-affinity receptor complex. Notably, these analogues stimulate peripheral blood mononuclear cells to generate lymphokine activated killing (LAK) while significantly reducing the secretion of IL-1.beta. and TNF-.alpha. compared to native IL-2. This research positions these analogues as valuable low-toxicity alternatives in human immunotherapy and adoptive immunotherapy treatment strategies.
Career Highlights
Keith Heaton is affiliated with the University of Texas System, where he conducts his research and development in immunotherapy. His work has garnered attention for its potential to revolutionize treatment strategies for various diseases, particularly in oncology. His dedication to advancing medical science is evident in his innovative approach to immunotherapy.
Collaborations
Keith collaborates with Elizabeth A. Grimm, a fellow researcher in the field. Their combined expertise enhances the research outcomes and contributes to the development of effective therapeutic strategies.
Conclusion
Keith Heaton's innovative work in developing low-toxicity interleukin-2 analogues represents a significant advancement in immunotherapy. His contributions have the potential to improve treatment options for patients, making a lasting impact in the medical field.